Assessing the mid-term impact of enhanced prostate cancer screening in Caucasian men with germline DNA repair pathogenic variants.

MLA

Lazzeri, Massimo, et al. “Assessing the Mid-Term Impact of Enhanced Prostate Cancer Screening in Caucasian Men with Germline DNA Repair Pathogenic Variants.” Journal of Clinical Oncology, vol. 42, Feb. 2024, p. 278. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.4_suppl.278.

APA

Lazzeri, M., Fasulo, V., Buffi, N. M., Casale, P., Hurle, R., Saita, A., Paciotti, M., Finocchiaro, A., Aljoulani, M., Asselta, R., Soldà, G., De Simone, I., Colombo, P., Cieri, M., Maura, F., Cavalli, P., & Lughezzani, G. (2024). Assessing the mid-term impact of enhanced prostate cancer screening in Caucasian men with germline DNA repair pathogenic variants. Journal of Clinical Oncology, 42, 278. https://doi.org/10.1200/JCO.2024.42.4_suppl.278

Chicago

Lazzeri, Massimo, Vittorio Fasulo, Nicolò Maria Buffi, Paolo Casale, Rodolfo Hurle, Alberto Saita, Marco Paciotti, et al. 2024. “Assessing the Mid-Term Impact of Enhanced Prostate Cancer Screening in Caucasian Men with Germline DNA Repair Pathogenic Variants.” Journal of Clinical Oncology 42 (February): 278. doi:10.1200/JCO.2024.42.4_suppl.278.